For research use only. Not for therapeutic Use.
Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation[1].
| Catalog Number | I042089 |
| CAS Number | 2456407-94-4 |
| Purity | ≥95% |
| Reference | [1]. Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538(22)01017-1. |
